Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2303]

Intratumoral BO-112 with pembrolizumab shows benefit in advanced melanoma...

Dr Iván Márquez-Rodas - Hospital General Universitario Gregorio Marañón, Madrid...

$Intratumoral BO-112 with pembrolizumab shows benefit in advanced melanoma refractory to anti-PD-1 therapy ( Dr Iván Márquez-Rodas - Hospital General Universitario Gregorio Marañón, Madrid, Spain )$

ASCO GU 2022: Prostate roundup

Prof Eleni Efstathiou, Prof Axel Merseburger and Dr Neal Shore

ASCO GU 2022: Prostate roundup ( Prof Eleni Efstathiou, Prof Axel Merseburger and Dr Neal Shore )

Safety and efficacy of olaparib plus metronomic cyclophosphamide and metformin...

Prof Benoit You - Hospices Civils de Lyon, Lyon, France

Safety and efficacy of olaparib plus metronomic cyclophosphamide and metformin in advanced/metastatic endometrial cancer ( Prof Benoit You - Hospices Civils de Lyon, Lyon, France )

Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid...

Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia

Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid tumours ( Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia )

Safety and efficacy of the oral ATR inhibitor elimusertib in advanced solid...

Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA

Safety and efficacy of the oral ATR inhibitor elimusertib in advanced solid tumours with DNA damage response defects ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )

PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1...

Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA

PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )

METNET: A phase II trial of metformin in patients with well differentiated...

Dr João Glasberg - Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil

METNET: A phase II trial of metformin in patients with well differentiated neuroendocrine tumours ( Dr João Glasberg - Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil )

EGFR testing: Best practice for NSCLC patients with exon 20 insertions

Dr Antonio Passaro, Dr Umberto Malapelle and Dr Joshua Sabari

EGFR testing: Best practice for NSCLC patients with exon 20 insertions ( Dr Antonio Passaro, Dr Umberto Malapelle and Dr Joshua Sabari )

ASCO GU 2022: Latest in mHSPC

Prof Eleni Efstathiou, Prof Karim Fizazi, Prof Kim Chi and Prof Matthew Smith

ASCO GU 2022: Latest in mHSPC ( Prof Eleni Efstathiou, Prof Karim Fizazi, Prof Kim Chi and Prof Matthew Smith )

ASCO GU 2022: PARP inhibitors in prostate and MAGNITUDE

Dr Neal Shore and Prof Kim Chi

ASCO GU 2022: PARP inhibitors in prostate and MAGNITUDE ( Dr Neal Shore and Prof Kim Chi )

SG in combination with pembro in patients with mUC who progressed after...

Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA

SG in combination with pembro in patients with mUC who progressed after platinum (PLT)-based regimens ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )

NMIBC treated with IL-15RαFc superagonist N-803 and BCG infusion

Prof Sam Chang - Vanderbilt University School of Medicine, Nashville, USA

NMIBC treated with IL-15RαFc superagonist N-803 and BCG infusion ( Prof Sam Chang - Vanderbilt University School of Medicine, Nashville, USA )

More from ecancer